Xingwei Xu

发表

Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.

A. Moretto, D. Joseph-McCarthy, T. Mansour, 2007, Journal of medicinal chemistry.

A combinatorial library of indinavir analogues and its in vitro and in vivo studies.

Yuan Cheng, Xin Xu, Lawrence C Kuo, 2002, Bioorganic & medicinal chemistry letters.

Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.

A. Moretto, T. Mansour, C. Hubeau, 2012, Journal of medicinal chemistry.

Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.

K. Svenson, J. Bard, T. Mansour, 2009, Journal of medicinal chemistry.

Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.

Xingwei Xu, Huan He, Ying Yang, 2019, Bioorganic & medicinal chemistry.

Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2.

Yuting Zhou, Tao Chen, Xingwei Xu, 2019, Bioorganic & medicinal chemistry.

Identification of 1,3-thiazinan-4-one urea-Based Derivatives as Potent FLT3/VEGFR2 Dual Inhibitors for the Treatment of Acute Myeloid Leukemia

Xingwei Xu, Ziwei Hu, Baohui Qi, 2021, Journal of Molecular Structure.

Discovery of a Novel Series of Imipridone Compounds as Homo sapiens Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.

Jiangnan Zhang, Tao Yang, Youfu Luo, 2022, Journal of medicinal chemistry.

Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.

J. D. Clark, M. Hegen, J. McKew, 2008, Journal of medicinal chemistry.

Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

K. Svenson, J. Bard, T. Mansour, 2013, ACS medicinal chemistry letters.

Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.

J. D. Clark, J. McKew, W. Abraham, 2008, Bioorganic & medicinal chemistry.

Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.

A. Moretto, T. Mansour, C. Hubeau, 2014, Journal of medicinal chemistry.

Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors.

D. Boschelli, Biqi Wu, Xiaoke Yang, 2010, Bioorganic & medicinal chemistry letters.

Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases

Xinyi Huang, Xin Xu, Shannon L. Stahler, 2011, The Journal of Biological Chemistry.

A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).

Wei Li, Xin Xu, Paul Morgan, 2009, Journal of medicinal chemistry.

Ovicidal and Insecticidal Activities of Pyriproxyfen Derivatives with an Oxime Ester Group

Xingwei Xu, L. Lin, Guoshao Sun, 2017, Molecules.

Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: selective inhibitors of 11β-hydroxysteroid dehydrogenase type I

J. Xiang, M. Tam, J. Tobin, 2005 .

Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.

J. McKew, E. A. Murphy, Xingwei Xu, 2009, Journal of medicinal chemistry.

Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.

Yuting Zhou, Xingwei Xu, Guowei Gong, 2020, European journal of medicinal chemistry.

Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.

Jun Yu Li, Tao Chen, Xingwei Xu, 2019, European journal of medicinal chemistry.

Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase Α2α

S. Khor, J. D. Clark, J. McKew, 2007 .

Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha.

S. Khor, J. McKew, M. S. Ku, 2007, Journal of medicinal chemistry.

Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).

J. Bard, T. Mansour, E. Saiah, 2012, Bioorganic & medicinal chemistry letters.

Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.

J. McKew, T. Mansour, J. Xiang, 2008, Journal of medicinal chemistry.

Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

J. Xiang, M. Tam, J. Tobin, 2005, Bioorganic & Medicinal Chemistry Letters.

Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.

Wei Li, Xin Xu, Paul Morgan, 2009, Journal of medicinal chemistry.

Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.

J. Xiang, E. Saiah, Zhao‐Kui Wan, 2011, Drug Metabolism Letters.

Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer.

Yuting Zhou, Xingwei Xu, Huan He, 2020, Bioorganic chemistry.